Lipella Pharmaceuticals Files 8-K
Ticker: LIPO · Form: 8-K · Filed: Nov 1, 2024 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Nov 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, corporate-event
TL;DR
Lipella Pharma filed an 8-K on Nov 1st, but it's light on details.
AI Summary
Lipella Pharmaceuticals Inc. filed an 8-K on November 1, 2024, reporting other events and financial statements. The filing does not contain specific financial figures or details about the nature of the 'Other Events' beyond its classification.
Why It Matters
This 8-K filing indicates a reportable event for Lipella Pharmaceuticals Inc., but lacks specific details on the nature or financial impact of the event.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with limited specific information, making it difficult to assess immediate risk.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- November 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Pittsburgh, PA (location) — Principal executive office location
FAQ
What specific event triggered this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as the items being reported, but does not specify the exact nature of the 'Other Events'.
When was the earliest event reported in this filing?
The earliest event reported was on November 1, 2024.
What is the principal executive office address of Lipella Pharmaceuticals Inc.?
The principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
In which state is Lipella Pharmaceuticals Inc. incorporated?
Lipella Pharmaceuticals Inc. is incorporated in Delaware.
What is the SIC code for Lipella Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Lipella Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-11-01 17:00:39
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar
Filing Documents
- g084523_8k.htm (8-K) — 33KB
- g084523_ex99-1.htm (EX-99.1) — 7KB
- 0001753926-24-001793.txt ( ) — 217KB
- lipo-20241101.xsd (EX-101.SCH) — 3KB
- lipo-20241101_lab.xml (EX-101.LAB) — 33KB
- lipo-20241101_pre.xml (EX-101.PRE) — 24KB
- g084523_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 1, 2024, Lipella Pharmaceuticals Inc. (the "Company") issued a press release announcing its intention to implement a one-for-eight reverse stock split of all of the Company's outstanding shares of common stock, par value $0.0001 per share, upon the filing of a certificate of amendment to the Company's second amended and restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware on November 7, 2024. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Forward-Looking Statements
Forward-Looking Statements Exhibit 99.1 attached hereto contains, and may implicate, forward-looking statements regarding the Company, and include cautionary statements identifying important factors that could cause actual results to differ materially from those anticipated. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 1, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 1, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer